Predicta Biosciences, a precision oncology company, has launched its first Laboratory Developed Test (LDT), GenoPredicta, for bone marrow or blood.
Conducted in a CLIA-approved laboratory, GenoPredicta measures genomic alterations, aiding physicians in diagnosing and managing multiple myeloma.
The test leverages genomic and immune profiling to support precision therapeutics.
It uses whole genome sequencing (WGS) to identify high-risk multiple myeloma patients, meeting the International Myeloma Society and International Myeloma Working Group standards.
The test reveals patients unlikely to respond to CAR-T and bispecific antibodies by identifying mutations in BCMA and GPRC5D.
Predicta co-founder Irene Ghobrial said: “Historically, diagnosing haematological malignancies has required bone marrow biopsies, which are intrusive and painful for patients, and fluorescence in situ hybridization (FISH) tests, which lack accuracy and reproducibility across labs, and are unable to detect some of the key molecular hallmarks of these types of cancers.
“Our new GenoPredicta test aims to overcome the many limitations in the diagnosis and prognosis of multiple myeloma, plasma cell malignancies and other blood cancers, and ultimately optimise treatment decisions for patients throughout their disease journey.”
The GenoPredicta test detects genomic alterations in tumour cells from bone marrow or blood, reducing reliance on FISH and similar diagnostics.
It evaluates prognostic cytogenetic variants and identifies additional variant types relevant for targeted therapy and immunotherapy selection.
GenoPredicta for Minimal Residual Disease (MRD) monitoring is expected later this year.
Predicta’s diagnostic platform, including GenoPredicta, has been used at the Dana-Farber Cancer Institute for prognosis and therapy response assessment in multiple myeloma.
The company aims to address unmet needs in blood cancer and autoimmune disease diagnostics with bone marrow and blood tests.
The launch of GenoPredicta follows a seed funding round in July last year, led by Engine Ventures.
Predicta plans to launch ImmunoPredicta, its second platform product that characterises the immune system for multiple myeloma patients, in 2026.
